Anne Constantino
Neurology · North Las Vegas, NVNPI 1134197221
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 31.0% of the total. Reporting peaked in 2019 at $829 and has fallen 86.5% since, to $112 in 2025. That places this record below the midpoint for neurology clinicians in NV, where the typical reported total is $1,327.
Across 86 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$467
- Teva Pharmaceuticals USA, Inc.$127
- Cala Health, Inc.$112
- UCB, Inc.$81
- Ipsen Biopharmaceuticals, Inc$66
- EMD Serono, Inc.$61
- plus $593 from 19 others
What the payments were for
- Speaking & faculty fees$342%
- Food & beverage$1,47398%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $467 |
| Teva Pharmaceuticals USA, Inc. | 4 | $127 |
| Cala Health, Inc. | 2 | $112 |
| UCB, Inc. | 6 | $81 |
| Ipsen Biopharmaceuticals, Inc | 3 | $66 |
| EMD Serono, Inc. | 4 | $61 |
| Lundbeck LLC | 4 | $57 |
| Lilly USA, LLC | 4 | $56 |
| MDD US Operations, LLC | 3 | $49 |
| Acadia Pharmaceuticals Inc | 3 | $48 |
| Acorda Therapeutics, Inc | 2 | $34 |
| AstraZeneca | 2 | $32 |
| Novartis | 2 | $31 |
| Adamas Pharmaceuticals, Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Vertical Pharmaceuticals, LLC | 2 | $30 |
| Merz North America, Inc. | 1 | $30 |
| Zyla Life Sciences, Inc. | 2 | $29 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| Grifols USA, LLC | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Boston Scientific | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Amgen | 1 | $13 |
How this compares
$1,507 in reported general payments places this provider in the 50th percentile of 145 neurology providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 14 | $1,424 |
| Divalproex Sodium | 12 | $772 |
| Donepezil Hcl | 11 | $212 |
Paid to pharmacies, not to this prescriber.
Other neurology in North Las Vegas
- Sherif HarawayNorth Las Vegas$10K
- Miracle WangsuwanaNorth Las Vegas$9K
- Melissa BlochReno$883K
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Burton TabaacReno$287K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.